Home » Stocks » FOLD

Amicus Therapeutics, Inc. (FOLD)

Stock Price: $18.26 USD -0.67 (-3.54%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed
After-hours: $18.76 +0.50 (2.74%) Oct 28, 7:38 PM

Stock Price Chart

Key Info

Market Cap 4.73B
Revenue (ttm) 226.94M
Net Income (ttm) -292.98M
Shares Out 258.79M
EPS (ttm) -1.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $18.26
Previous Close $18.93
Change ($) -0.67
Change (%) -3.54%
Day's Open 18.58
Day's Range 17.96 - 18.59
Day's Volume 1,299,627
52-Week Range 6.25 - 19.46

More Stats

Market Cap 4.73B
Enterprise Value 4.62B
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 258.79M
Float 253.61M
EPS (basic) -1.14
EPS (diluted) -1.14
FCF / Share -1.05
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 29.83M
Short Ratio 14.72
Short % of Float 11.76%
Beta 1.17
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 20.82
PB Ratio 12.92
Revenue 226.94M
Operating Income -272.65M
Net Income -292.98M
Free Cash Flow -271.62M
Net Cash 107.37M
Net Cash / Share 0.41
Gross Margin 70.62%
Operating Margin -120.14%
Profit Margin -129.10%
FCF Margin -119.69%
ROA -21.04%
ROE -60.97%
ROIC -50.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (11)

Buy 9
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$20.09*
(10.02% upside)
Low
12.0
Current: $18.26
High
31.0
Target: 20.09
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue18291.2536.934.96-1.220.3618.4121.430.92
Revenue Growth99.72%147.08%644.86%--237.19%-98.03%-14.1%2224.73%-
Gross Profit16076.8430.694.13-1.220.3618.4121.430.92
Operating Income-301-325-676-175-126-68.60-64.18-52.93-50.89-55.84
Net Income-356-349-284-200-132-68.93-59.63-48.79-44.41-54.94
Shares Outstanding24018615313411074.4451.2945.5734.5727.73
Earnings Per Share-1.48-1.88-1.85-1.49-1.20-0.931.161.07-1.28-1.98
EPS Growth------8.41%---
Operating Cash Flow-250-300-214-150-100-51.67-45.79-33.74-49.42-13.98
Capital Expenditures-20.01-6.31-4.53-5.95-4.82-0.24-0.70-4.32-1.42-0.38
Free Cash Flow-270-306-218-156-105-51.91-46.49-38.07-50.84-14.37
Cash & Equivalents45350435933021415282.0099.1255.70107
Total Debt210322164154-14.3514.470.701.042.34
Net Cash / Debt24318219417621413767.5398.4354.66105
Assets8507906271,03790821012811069.80113
Liabilities37444727467756187.7981.8140.8740.2047.62
Book Value47634335336034812245.7569.2229.5964.93
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Amicus Therapeutics, Inc.
Country United States
Employees 584
CEO John Francis Crowley

Stock Information

Ticker Symbol FOLD
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FOLD
IPO Date May 31, 2007

Description

Amicus Therapeutics, a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.